Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

1.

Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study.

Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M, Holstein P, Jude E, Jirkovska A, Mauricio D, Piaggesi A, Reike H, Spraul M, Van Acker K, Van Baal S, Van Merode F, Uccioli L, Urbancic V, Ragnarson Tennvall G.

Diabetologia. 2008 Oct;51(10):1826-34. doi: 10.1007/s00125-008-1089-6. Epub 2008 Jul 22.

PMID:
18648766
[PubMed - indexed for MEDLINE]
2.

High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study.

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, van Baal J, van Merode F, Schaper N.

Diabetologia. 2007 Jan;50(1):18-25. Epub 2006 Nov 9.

PMID:
17093942
[PubMed - indexed for MEDLINE]
3.

Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.

Ghatnekar O, Persson U, Willis M, Odegaard K.

Pharmacoeconomics. 2001;19(7):767-78.

PMID:
11548912
[PubMed - indexed for MEDLINE]
4.

Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study.

Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, Uccioli L, Urbancic V, Bakker K, Holstein P, Jirkovska A, Piaggesi A, Ragnarson-Tennvall G, Reike H, Spraul M, Van Acker K, Van Baal J, Van Merode F, Ferreira I, Huijberts M.

Diabetologia. 2008 May;51(5):747-55. doi: 10.1007/s00125-008-0940-0. Epub 2008 Feb 23.

PMID:
18297261
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds.

Apelqvist J, Armstrong DG, Lavery LA, Boulton AJ.

Am J Surg. 2008 Jun;195(6):782-8. doi: 10.1016/j.amjsurg.2007.06.023. Epub 2008 Mar 26.

PMID:
18355797
[PubMed - indexed for MEDLINE]
6.

Costs of deep foot infections in patients with diabetes mellitus.

Tennvall GR, Apelqvist J, Eneroth M.

Pharmacoeconomics. 2000 Sep;18(3):225-38.

PMID:
11147390
[PubMed - indexed for MEDLINE]
7.

[Economic aspects of the diabetic foot syndrome].

Cechurová D, Lacigová S, Rusavý Z, Horáková N, Jankovec Z, Zourek M.

Vnitr Lek. 2003 Jun;49(6):453-6. Czech.

PMID:
14503473
[PubMed - indexed for MEDLINE]
8.

Optimal organization of health care in diabetic foot disease: introduction to the Eurodiale study.

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Tennvall GR, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, Van Baal J, Van Merode F, Schaper N.

Int J Low Extrem Wounds. 2007 Mar;6(1):11-7.

PMID:
17344196
[PubMed - indexed for MEDLINE]
9.

Management of diabetic foot lesions in hospital: costs and benefits.

Benotmane A, Mohammedi F, Ayad F, Kadi K, Medjbeur S, Azzouz A.

Diabetes Metab. 2001 Dec;27(6):688-94.

PMID:
11852378
[PubMed - indexed for MEDLINE]
Free Article
10.

Diabetes--inpatient utilisation, costs and data validity. Dunedin 1985-9.

Phillips DE, Mann JI.

N Z Med J. 1992 Aug 12;105(939):313-5.

PMID:
1501816
[PubMed - indexed for MEDLINE]
11.

Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain.

Rivera J, Rejas J, Esteve-Vives J, Vallejo MA; Groupo ICAF.

Clin Exp Rheumatol. 2009 Sep-Oct;27(5 Suppl 56):S39-45.

PMID:
20074438
[PubMed - indexed for MEDLINE]
12.

Hospitalisation costs of cystic fibrosis.

Schreyögg J, Hollmeyer H, Bluemel M, Staab D, Busse R.

Pharmacoeconomics. 2006;24(10):999-1009.

PMID:
17002482
[PubMed - indexed for MEDLINE]
13.

Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study.

Papanicolaou S, Pons ME, Hampel C, Monz B, Quail D, Schulenburg MG, Wagg A, Sykes D.

Maturitas. 2005 Nov 30;52 Suppl 2:S35-47. Epub 2005 Nov 16.

PMID:
16297577
[PubMed - indexed for MEDLINE]
14.

Costs and medical care consequences associated with the diagnosis of peripheral arterial disease.

Migliaccio-Walle K, Caro JJ, Ishak KJ, O'Brien JA.

Pharmacoeconomics. 2005;23(7):733-42.

PMID:
15987229
[PubMed - indexed for MEDLINE]
15.

A model to analyse costs and benefit of intensified diabetic foot care in Austria.

Habacher W, Rakovac I, Görzer E, Haas W, Gfrerer RJ, Wach P, Pieber TR.

J Eval Clin Pract. 2007 Dec;13(6):906-12.

PMID:
18070261
[PubMed - indexed for MEDLINE]
16.

Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study.

Liebl A, Breitscheidel L, Nicolay C, Happich M.

Curr Med Res Opin. 2008 Aug;24(8):2349-58. doi: 10.1185/03007990802292728. Epub 2008 Jul 4.

PMID:
18606055
[PubMed - indexed for MEDLINE]
17.

Topical treatment of diabetic foot ulcers: an economic analysis of treatment alternatives and strategies.

Apelqvist J, Ragnarson-Tennvall G, Larsson J.

Diabet Med. 1995 Feb;12(2):123-8.

PMID:
7743758
[PubMed - indexed for MEDLINE]
18.

[Calculation of the costs of drugs, medical materials, certain medical procedures and social services for patients with diabetic foot syndrome].

Brunerová L, Andĕl M.

Vnitr Lek. 2003 Jun;49(6):457-64. Czech.

PMID:
14503474
[PubMed - indexed for MEDLINE]
19.

An assessment of the disease burden of foot ulcers in patients with diabetes mellitus attending a teaching hospital in Lagos, Nigeria.

Ogbera AO, Fasanmade O, Ohwovoriole AE, Adediran O.

Int J Low Extrem Wounds. 2006 Dec;5(4):244-9.

PMID:
17088600
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk